Impact Factor
3.09
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.40
3,437 total citations
h5-index
67
h5 depth signal
Cited share
21.0%
544 of 2,592
Total citations
3,437
Citation footprint
Metric signal
1.51
External metric anchor
Self-citation
2.3%
79 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,334
Italy
781
Netherlands
767
United Kingdom
720
China
628
Citing Fields of Research
Lipids
5,102
Cardiology
4,877
Diabetes
2,132
Endocrinology & Metabolism
2,070
Vascular Disorders
1,310
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
36,861
Articles tracked across the journal lifetime
Indexed publication set
2,592
544 cited publications
Last 12 months
1,285
107.1 publications/month
Open access share
10.0%
129 OA publications in the last year
Leading citing country
United States
1,334 citing publications
Leading citing field
Lipids
5,102 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v11n1,Jan./Feb. 1970-
v11n1,Jan./Feb. 1970-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Lipids
Broad Categories
Vascular Diseases
Lipids
Cardiology
Vascular Disorders
Diabetes
Urology
MeSH Descriptors
Arteriosclerosis
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.atherosclerosis.2026.121929
Open DOI
PlGF modulates vascular smooth muscle cells phenotype to enhance atherosclerotic plaque stability
02
DOI 10.1016/j.atherosclerosis.2026.121922
Open DOI
Association between elevated lipoprotein (a) and venous thromboembolism: A systematic review and meta-analysis
03
04
DOI 10.1016/j.atherosclerosis.2026.121920
Open DOI
Development and external validation of a non-laboratory model to predict early-onset cardiovascular disease risk: a multicohort machine learning study
05
DOI 10.1016/j.atherosclerosis.2026.121924
Open DOI
Macrophage-Derived TNF-α Promotes Vascular Inflammation and Cell Crosstalk in Human Atherosclerotic Plaques via TNFRSF1A
06
DOI 10.1016/j.atherosclerosis.2026.121927
Open DOI
ST3GAL1-mediated α-2,3 sialylation restrains CD105–TGFβRII signaling to attenuate EndMT-driven atherosclerosis
07
DOI 10.1016/j.atherosclerosis.2026.121919
Open DOI
Association of beta-blocker therapy with outcomes after ST-segment elevation myocardial infarction stratified by GRACE risk score: A nationwide registry analysis
08
DOI 10.1016/j.atherosclerosis.2026.121928
Open DOI
Lp(a) reduction with PCSK9 inhibitors: How does real-world data stack up?
09
DOI 10.1016/j.atherosclerosis.2026.121926
Open DOI
Beyond a single measurement: the role of cumulative LDL-C exposure after percutaneous coronary intervention
10
DOI 10.1016/j.atherosclerosis.2026.121917
Open DOI
Immune-inflammatory profiles, coronary artery disease, and peripheral artery disease in people with HIV
Bibliographical & Catalog Notes
Some v. have supplements, -July 2000. Beginning Sept. 2000, supplements issued in a separately numbered journal: Atherosclerosis. Supplements.
Also issued online.
Some articles in German, with English summary.
Vol. 76, no. 1 (MAR 1989)19900914 Notice published Printed on acid-free paper